EMILIO PAGAN TORRES MD
Prescription History 1629661939
General Practice in Mayaguez, PR

NPI Status: Active since February 17, 2021

Contact Information

AVE. HOSTOS 410 CARR #2
MAYAGUEZ, PR
ZIP 00680
Phone: (787) 652-9200

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for EMILIO PAGAN TORRES MD, an active General Practice specialist practicing in Mayaguez, PR. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 13 documented patient claims. Among these therapy options, the most frequently utilized medication is Jentadueto, which accounts for 13 claims alone.

Medication Index

No matching medications currently found on file.

Jentadueto

Generic Formulation: Linagliptin/Metformin HclSpecialty: General Practice
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
PR State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills42.5
Peer Average Days Supply1,271
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.2% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,944.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$534.18

State Avg Cost Per Claim

$707.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Linagliptin/metformin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. This product contains 2 medications: linagliptin and metformin. Linagliptin works by increasing levels of natural substances called incretins. Incretins help to control blood sugar by increasing insulin release, especially after a meal. They also decrease the amount of sugar your liver makes. Metformin works by helping to restore your body's proper response to the insulin you naturally produce. It also decreases the amount of sugar that your liver makes and that your stomach/intestines absorb.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like EMILIO PAGAN TORRES MD provides transparency into local medical care patterns within Mayaguez, PR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **General Practice** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.